The Economic and Mortality Impact of Stock-Outs of TB Medicines. Edmund Rutta, MD MPH SIAPS Bangkok, March 2-6, 2015
|
|
- Sabrina Walters
- 5 years ago
- Views:
Transcription
1 The Economic and Mortality Impact of Stock-Outs of TB Medicines Edmund Rutta, MD MPH SIAPS Bangkok, March 2-6, 2015
2 Background A 2013 study in the Philippines found that: Only 7% of 583 MDR-TB patients completed treatment without interruption Patients who had longer interruptions with sporadic variability during the 6 12 month or the month treatment period had a significantly increased risk for poor outcomes compared to patients who had short, regular interruptions Patients that miss more consecutive days of treatment with sporadic interruption patterns or a greater proportion of treatment are at an increased risk for poor treatment outcomes Source: Podewils LJ, Gler MTS, Quelapio MI, Chen MP (2013) Patterns of Treatment Interruption among Patients with Multidrug-Resistant TB (MDR TB) and Association with Interim and Final Treatment Outcomes. PLoS ONE 8(7): e doi: /journal.pone
3 Impact of Reducing Stock-Outs Treatment interruption is likely to result in poor treatment outcomes and investment in reducing it may be very worthwhile An example of a poor treatment outcome is that interruption could lead a DS-TB patient to develop MDR-TB But treatment interruption also results in wasted resources For example, investments in lab services that are not followed up by successful treatment We often think that treatment interruption is a patient issue but it can also be due to stock-outs, which is a preventable problem
4 Treatment Interruption Impact Tool (TIIT) SIAPS is developing a tool to estimate the impact of stock-outs which can be used to advocate for greater investment in solving stock-out problems The tool can also be: Used to estimate the impact of TB patient nonadherence Adapted to ARVs, diseases that involve specific medicines, and laboratory supply stock-outs
5 The TIIT Tool Excel-based, open source, will be available online Now in prototype version Consultations with experts indicate that there is little knowledge on the impact of treatment interruption and it has not previously been costed Your feedback will be important and appreciated
6 How the Tool Works: Phases Separate algorithm for each of 4 treatment phases: Drug Susceptible TB (first-line): Initial phase Continuation phase Drug Resistant TB (second-line): Initial phase Continuation phase
7 Prototype Assumptions This initial version was intended to be as simple as possible but we can add other areas if they are important This version assumes 2 months of stock-out (the final version will include a 1 month and a 3 month model) It assumes stock-outs of all drugs needed, not one or two of the drugs in the package (which could be more serious) The health and treatment implications are based mainly on evolving expert judgment with some assumptions used to test the model (e.g. the percentage of persons who would use the private sector if the public sector has a stock-out) The unit costs are from Indonesia where we have conducted several costing studies
8 Example of the Data Entry and Costing Table MDR-TB Initial Phase Unit cost Total cost Key assumptions Length of stock-out in months 2 Patients affected by stock out 100 Number who buy drugs in private sector 25% Additional cost of medicines Additional monthly cost per patient $ 793 Total cost of medicines per patient $ 1,586 Total cost of medicines for all patients $ 39, Increased risk of XDR-TB due to poor quality drugs 50% 12.5 Cost per patient of diagnosing and treating MDR-TB $ 26,392 Total cost of patients who convert to XDR-TB due to poor quality medicines $ 329,900 Assumed good quality - no cost $ Increased risk of infecting other persons with MDR-TB Number of persons who could be infected 25 Number of persons who would develop MDR-TB 10% 2.5 Cost of treating one MDR-TB case 10,032 Total cost of treating persons who become infected with MDR-TB $ 25,080 Sub-total $ 394,626
9 Example of One of the Decision Trees 25% Number who buy drugs in private sector 50% Increased risk of XDR-TB due to poor quality 25 50%?? Die?? 70% Number who resume treatment and are cured MDRTB initial phase 100 0% Number who resume tre 20% Number who resume treatment but die 0 75% Number who go without drugs 75 10% Number who become XDR-TB cases 0% Number who will self-cure 100% Number who do not resume treatment % Number who die
10 Summary of Prototype Results for 100 People Without Access to Medicines for 2 Months (Results Not To Be Added) Phase US$ DS-TB initial phase 55,622 DS-TB continuation phase 355,039 MDR-TB initial phase 1,228,816 MDR-TB continuation phase 782,177
11 Summary of MDR-TB Initial Phase Stock-Out Impact by Component SUMMARY Initial Phase Assume 2 months stock-out for 100 Patients % # people Cost Number who buy drugs in private sector 25% 25 Additional cost of medicines $ 39,646 Increased risk of XDR-TB due to poor quality drugs $ 329,900 Increased risk of infecting other persons with MDR-TB $ 25,080 Sub-total $ 394,626 Number who go without drugs 75% 75 Number who resume treatment Number who resume treatment and are cured $ 33,989 Number who resume treatment but die $ 54,855 Number who become XDR-TB cases $ 123,620 Number who do not resume treatment $ 205,950 Number of new infections transmitted $ 183,285 Number of persons for whom sunken treatment costs were incurred $ 232,493 Sub-total $ 834,191 GRAND TOTAL $ 1,228,816
12 Next Steps Finalize prototype Internal review of prototype additions/changes Circulate to selected experts and review assumptions Show deaths? (DALYs too complex?) Cost partial packages? Conduct literature review to look for evidence Use tool to conduct analysis for target countries Kenya, Bangladesh, Tanzania and Philippines? Compare with costs of reducing stock-outs (investment case) For more information contact Edmund Rutta and David Collins
13 Thank you
The Economic Cost of Non-adherence to TB Medicines Resulting from Stock-outs and Loss to Follow-up in Kenya
The Economic Cost of Non-adherence to TB Medicines Resulting from Stock-outs and Loss to Follow-up in Kenya March 2017 Photo Credit: Francis Nsanga UHMG, Photoshare, Kenya RESEARCH SUMMARY A key element
More informationEconomic Cost of Non-Adherence to TB Medicines Resulting from Stock-Outs and Loss to Follow-Up in the Philippines
Economic Cost of Non-Adherence to TB Medicines Resulting from Stock-Outs and Loss to Follow-Up in the Philippines December 2016 Economic Cost of Non-Adherence to TB Medicines Resulting from Stock-Outs
More informationThe Economic Cost of Non-adherence to TB Medicines Kenya
The Economic Cost of Non-adherence to TB Medicines Kenya 1 The Economic Cost of Non-adherence to TB Medicines Kenya This report is made possible by the generous support of the American people through the
More informationGuidance on Matching Funds: Tuberculosis Finding the Missing People with TB
February 2017 Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB 1. Background TB is the leading cause of death by infectious disease, killing 1.8 million people in 2015. Each
More informationFinding the missing TB cases
Finding the missing TB cases Optimizing strategies to enhance case detection in high HIV burden settings Dr Malgosia Grzemska Global TB Programme, WHO/HQ, Geneva SWITZERLAND Child and Adolescent TB Working
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More information4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB
Sindy M. Paul, MD, MPH, FACPM May 1, 2012 The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB morbidity, including resistance Identifying people
More informationGlobal, National, Regional
Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology
More informationGlobal, National, Regional
Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationXpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10
Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10 Introduction Excellent performances, rapid results, and easy to use Questions Where and how are we going
More informationTB Disease Prevalence Survey - Overview, why and how
TB Disease Prevalence Survey - Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force on TB Impact Measurement Stop TB Department, WHO onozakii@who.int 3 strategic
More informationRevised National Tuberculosis Control Programme
Revised National Tuberculosis Control Programme 1 OUTLINE OF PRESENTATION Introduction Burden Of The Disease Evolution Of RNTCP Goals And Objectives Of RNTCP DOTS Stop TB Strategy Organization RNTCP Endorsed
More informationThe WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps
The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps Matteo Zignol STOP TB Department World Health Organization TB surveillance and
More informationControlling TB in the era of HIV
Controlling TB in the era of HIV Christy Hanson, PhD, MPH TB Research Advisor Amy Bloom, MD TB/HIV Advisor TB Incidence rates highest in Africa Estimated new TB cases (all forms) per 100 000 population
More informationCost-Effectiveness Analysis of TB Diagnostics David Dowdy Challenges and Future Directions
Cost-Effectiveness Analysis of TB Diagnostics David Dowdy ddowdy@jhsph.edu Challenges and Future Directions Objectives Provide an overview of cost-effectiveness analysis (CEA) as applied to TB diagnostics
More informationXpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection. Results of Group Work
Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection Results of Group Work DOTS expansion and enhancement Objective This group deals with the majority
More informationEffectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) M Bonnet, M Bastard, P du Cros, K Atadjan, K Kimenye, S Khurkhumal, A Hayrapetyan, A Telnov, C Hewison, F Varaine
More informationANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM
ANNEXURE A: EXPLANATORY NOTES ON THE DMR 164 REPORTING ON HIV AND TB FORM The form and content of the explanatory note is to: Inform those responsible for completing the DMR 164 Reporting Form - as to
More informationTB Program and Epidemic aka B2B
TB Program and Epidemic aka B2B Nulda Beyers On behalf of DTTC BOD Workshop 30 September2013 Trend in tuberculosis incidence, selected countries in Africa 1400 1200 Rate per 100,000 1000 800 600 400 200
More informationCost Effectiveness of New Diagnostics for TB
Cost Effectiveness of New Diagnostics for TB David Bishai, Megan O Brien, David Dowdy Johns Hopkins University October 10, 2007 Outline Objectives What combinations of sensitivity and price would result
More informationEstimates of TB incidence, prevalence and mortality. Philippe Glaziou Cairo, October 2009
Estimates of TB incidence, prevalence and mortality Philippe Glaziou Cairo, October 2009 Outline Main sources of information Incidence From incidence to prevalence From incidence to mortality TB/HIV MDR-TB
More informationTB Disease Prevalence Survey - Overview and Introduction of the TF
TB Disease Prevalence Survey - Overview and Introduction of the TF Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force on TB Impact Measurement Stop TB Department, WHO onozakii@who.int
More informationThe United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America
The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America Mike Segar / Reuters Executive Summary Context On 26 September 2018, the United Nations
More informationCost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
RESEARCH ARTICLE Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK Lara J. Wolfson 1 *, Anna Walker 2, Robert Hettle 2, Xiaoyan Lu
More informationLa Lotta alla Tubercolosi. Matteo Zignol and Mario C. Raviglione Stop TB Department WHO, Geneva, Switzerland. Geneva March 2012
La Lotta alla Tubercolosi Matteo Zignol and Mario C. Raviglione Stop TB Department WHO, Geneva, Switzerland Geneva 19-20 March 2012 Overview of the presentation The global burden of tuberculosis The WHO
More information7.5 South-East Asian Region: summary of planned activities, impact and costs
PART II: GLOBAL AND REGIONAL SCENARIOS FOR TB CONTROL 26 215 7.5 South-East Asian Region: summary of planned activities, impact and costs Achievements DOTS expanded rapidly in the South-East Asian Region
More informationTB in California: Costs, Transmission, and Selecting from the Latent Pool
TB in California: Costs, Transmission, and Selecting from the Latent Pool Pennan Barry, MD, MPH Tuberculosis Control Branch California Department of Public Health California Tuberculosis Controller s Association
More informationCosting of the Sierra Leone National Strategic Plan for TB
Costing of the Sierra Leone National Strategic Plan for TB 2016-2020 Introduction The Government of Sierra Leone established the National Leprosy Control Programme in 1973 with support from the German
More informationKenya Perspectives. Post-2015 Development Agenda. Tuberculosis
Kenya Perspectives Post-2015 Development Agenda Tuberculosis SPEAKERS Anna Vassall Anna Vassall is Senior Lecturer in Health Economics at the London School of Hygiene and Tropical Medicine. She is a health
More informationStop TB Working Group on DOTS-Plus for MDR-TB Strategic Plan
Stop TB Working Group on DOTS-Plus for MDR-TB Strategic Plan 2006-2015 Background Current threat and status of the global epidemic of multidrug resistant tuberculosis (MDR-TB) Along with HIV/AIDS, MDR-TB
More informationModeling the Cost-Effectiveness of Multi-Drug Resistant Tuberculosis Diagnostic and Treatment Services in Indonesia
Modeling the Cost-Effectiveness of Multi-Drug Resistant Tuberculosis Diagnostic and Treatment Services in Indonesia David H. Collins and Zina M. Jarrah of Management Sciences for Health November 2013 Management
More informationPresented by Leigh Snyman April 2017
Presented by Leigh Snyman April 2017 Overview Definition of Palliative Care Case based discussion Take home messages What is Palliative Care? WHO Definition of Palliative Care: Palliative care is an approach
More informationModelling HIV prevention: strengths and limitations of different modelling approaches
Modelling HIV prevention: strengths and limitations of different modelling approaches Leigh Johnson Centre for Infectious Disease Epidemiology and Research Background Models of HIV differ greatly in their
More informationXDR and MDR TB Urgent Research Priorities. Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine
XDR and MDR TB Urgent Research Priorities Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine The Year of MDR XDR TB CDC, WHO report on global XDR TB XDR TB defined Global distribution
More informationThe epidemiology of tuberculosis
The epidemiology of tuberculosis Tuberculosis Workshop Shanghai, 12-22 May 28 Philippe Glaziou World Health Organization Outline Epidemiology refresher Estimates of tuberculosis disease burden Notifications
More informationDrug-resistant Tuberculosis
page 1/15 Scientific Facts on Drug-resistant Tuberculosis Source document: WHO (2008) Summary & Details: GreenFacts Level 2 - Details on Drug-resistant Tuberculosis 1. What is tuberculosis and why is it
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationMONITORING COMPASSIONATE USE OF NEW DRUGS FOR TUBERCULOSIS
MONITORING COMPASSIONATE USE OF NEW DRUGS FOR TUBERCULOSIS MONITORING COMPASSIONATE USE OF NEW DRUGS FOR TUBERCULOSIS Compassionate Use (CU) programs have been utilized for new cancer and HIV drugs to
More informationSummary of the risk management plan (RMP) for Sirturo (bedaquiline)
EMA/16634/2014 Summary of the risk management plan (RMP) for Sirturo (bedaquiline) This is a summary of the risk management plan (RMP) for Sirturo, which details the measures to be taken in order to ensure
More informationTuberculosis Epidemiology
Tuberculosis Epidemiology TB CLINICAL INTENSIVE COURSE Curry International Tuberculosis Center October 18, 2017 Varsha Hampole, MPH Tuberculosis Control Branch California Department Of Public Health Outline
More informationGLOBAL TUBERCULOSIS REPORT EXECUTIVE SUMMARY
GLOBAL TUBERCULOSIS REPORT EXECUTIVE SUMMARY 2018 Context On 26 September 2018, the United Nations (UN) will hold its first highlevel meeting on tuberculosis (TB), at its headquarters in New York. The
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationIndicators for MDR-TB detection and outcomes
Indicators for MDR-TB detection and outcomes Dennis FALZON TB surveillance and surveys: A training workshop for consultants Geneva, Switzerland - 26 May 2011 Reference 2 Aggregated forms pages 161 162
More informationDrug resistance in tuberculosis in South-East Asia
Drug resistance in tuberculosis in South-East Asia Vineet Bhatia*, Md Khurshid Alam Hyder* and Nani Nair* Abstract The South-East Asia Region (SEAR) of WHO bears around one third of the global burden of
More informationImplementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation
Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB Global Consultation Geneva, 30 November 2010 Mario C. Raviglione, M.D. Director, Stop TB Department WHO, Geneva,
More informationAntimicrobial resistance Fact sheet N 194 Updated April 2014
Antimicrobial resistance Fact sheet N 194 Updated April 2014 Key facts Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by
More informationVirtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine
Virtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine 3rd sector OR and developing countries 27th March 2013, London School of Economics
More informationInternational Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007
TB Along the US/Mexico Border El Paso, Texas August 22-23, 2007 International Standards for Tuberculosis Care Barbara J. Seaworth, MD August 22, 2007 Barbara J Seaworth MD Medical Director Heartland National
More informationGlobal Burden of Respiratory Disease Lessons from Afar Scott Barnhart, MD, MPH June 18, 2010
Global Burden of Respiratory Disease Lessons from Afar Scott Barnhart, MD, MPH June 18, 2010 Scott Barnhart, MD, MPH June 18, 2010 Three Goals An Overview of the global burden of respiratory disease relative
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationTransmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos
Transmissibility, virulence and fitness of resistant strains of M. tuberculosis CHIANG Chen-Yuan MD, MPH, DrPhilos Transmissibility, Virulence and Fitness of resistant strains of M. tuberculosis For infectious
More informationAnnex A: Impact, Outcome and Coverage Indicators (including Glossary of Terms)
IMPACT INDICATORS (INDICATORS PER GOAL) HIV/AIDS TUBERCULOSIS MALARIA Reduced HIV prevalence among sexually active population Reduced HIV prevalence in specific groups (sex workers, clients of sex workers,
More informationExisting approaches to costing, financing and estimating cost-efficiencies for nutrition
Existing approaches to costing, financing and estimating cost-efficiencies for nutrition February 2016 Meera Shekar Global Lead for Nutrition 1 Global Stunting Rates 159 million children stunted worldwide
More informationShort Course Treatment for MDR TB
Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize
More informationThe emerging threat of multidrug resistant TB: Global and local challenges and solutions
Summary of IOM-ASSAf Workshop on: The emerging threat of multidrug resistant TB: Global and local challenges and solutions Salim S. Abdool Karim Pretoria - March, 2010 Why this workshop? Why is it on MDR
More informationTB Disease Prevalence Survey - Progress Report
TB Disease Prevalence Survey - Progress Report 30 Oct 2011, Lille Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force on TB Impact Measurement Stop TB Department, WHO onozakii@who.int
More informationSouth West. Tuberculosis Treatment Outcome Surveillance for the South West
South West Tuberculosis Treatment Outcome Surveillance for the South West 2001-2004 Outcome Surveillance 2001-2004 TB Outcome Surveillance 2001-2004 Data for the South West Region, England A report from
More information2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationDeveloping a Rights-Based Approach to Prevention and Treatment of Tuberculosis in India
University of Chicago Center in Delhi Developing a Rights-Based Approach to Prevention and Treatment of Tuberculosis in India Organizers United States: Evan Lyon, MD Assistant Professor of Medicine, Department
More informationEssential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective
Essential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective James Watt, MD, MPH Acting Chief, Tuberculosis Control Branch California Department of Public
More informationScaling up priority HIV/AIDS interventions in the health sector
TOWARDS UNIVERSAL ACCESS? Scaling up priority HIV/AIDS interventions in the health sector Yves Souteyrand, WHO October 2011 Towards universal access targets UN General Assembly High level Meeting June
More informationTB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director
TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition
More informationThe Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC
The Comprehensive Package: The simple truth about our response to drug related HIV Dr. Monica Beg, Signe Rotberga UNODC HIV among injecting drug users Why is it so important? 30% global HIV infections
More informationLet s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Abstract Nearly 50% of patients with
More informationThe Impact of Effective Treatment on TB Transmission FAST: A re-focused, intensified, administrative approach to institutional TB transmission control
The Impact of Effective Treatment on Transmission FAST: A re-focused, intensified, administrative approach to institutional transmission control Edward A. Nardell, MD Professor of Medicine Brigham & Women
More information#4 (Tuberculosis OR TB OR Pulmonary Tuberculosis OR Multi-Drug Resistant Tuberculosis OR MDR OR Extremely-Drug Resistant Tuberculosis or XDR)
DATABASE Cochrane Database of Systematic Reviews DATE 15 DECEMBER 2015 #1 Safety of Crucell Ad35/ AERAS-402 OR Effectiveness of Crucell Ad35/ Aeras-402 OR Safety of MVA85A/ Aeras-485 OR Effectiveness of
More informationMultidrug-Resistant TB
Multidrug-Resistant TB Diagnosis Treatment Linking Diagnosis and Treatment Charles L. Daley, M.D. National Jewish Health University of Colorado Denver Disclosures Chair, Data Monitoring Committee for delamanid
More informationDrug resistance surveillance: progress to date and emerging innovations
Drug resistance surveillance: progress to date and emerging innovations Anna Dean Matteo Zignol WHO Global Task Force on TB Impact Measurement Glion-sur-Montreux 19 21 April 2016 1. Global project on anti-tb
More informationScale up of MDR TB Management in the Philippines: Lessons Learned
Scale up of MDR TB Management in the Philippines: Lessons Learned Tropical Disease Foundation in collaboration with the NTP, Department of Health Ma. Imelda D. Quelapio, MD Philippines: Magnitude of the
More informationResearch Excellence to Stop TB Resistance. Plan for MDR-TB Clinical Trials: An Overview March 9, 2010
RESIST-TB: Summary Research Excellence to Stop TB Resistance Plan for MDR-TB Clinical Trials: An Overview March 9, 2010 The current epidemic of Multidrug-Resistant Tuberculosis (MDR-TB) is a major threat
More informationQuestions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs
Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs What causes TB? TB is caused by the bacterium Mycobacterium tuberculosis. Although it can cause disease in
More informationSirturo: a new treatment against multidrug resistant tuberculosis
Sirturo: a new treatment against multidrug resistant tuberculosis TB is an on-going problem WHO estimated incidence of new TB cases 2009 Global Tuberculosis Control: WHO report 2010. Available at: http://www.who.int/tb/publications/global_report/2010/en/index.html
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationIn Vitro Diagnostic Platforms for the Developing World. David Kelso Oak Ridge April 20, 2012
In Vitro Diagnostic Platforms for the Developing World David Kelso Oak Ridge April 20, 2012 Center for Innovation in Global Health Technologies Academia Key Contributions: Project Coordination, New Technology,
More informationTB surveillance. Philippe Glaziou Dubrovnik, May 2009
TB surveillance Philippe Glaziou Dubrovnik, May 2009 What are the global TB targets? Outcome targets (World Health Assembly, STB Partnership) Case detection ratio > 70% Treatment success > 85% 2015 Impact
More informationXDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps
XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever
More informationStrengthening Lab Capacity for TB Diagnosis and Care in LMICs
Strengthening Lab Capacity for TB Diagnosis and Care in LMICs Raising the Bar June 20, 2018 Advanced TB Diagnostics Course McGill University, Montreal Kathleen England, PhD MSc TB Diagnostics Advisor MSF
More information2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges
Outline of what it will take Tuberculosis Elimination 25: Global and Local Challenges Anne Fanning, MD November 9, 211 21 global TB trends, goals How DOTS happens at country level - an exercise New strategies
More informationRevitalising community engagement for TB and TB/HIV prevention, diagnosis and treatment
17 th TB/HIV Core Group meeting, Beijing, China. November 11, 2011 Revitalising community engagement for TB and TB/HIV prevention, diagnosis and treatment Haileyesus Getahun Stop TB Department WHO Outline
More informationPalliative Care for Patients with Drug Resistant Tuberculosis The missing piece of the puzzle! What can TB learn from HIV?
Palliative Care for Patients with Drug Resistant Tuberculosis The missing piece of the puzzle! What can TB learn from HIV? AWA CC ^ Dr. Thilo Govender Public Health Medicine Specialist 7 October 2016 Acknowledgements
More informationIncreasing Access to Medicines through Accredited Drug Dispensing Outlets (ADDOs): An Innovative Public-Private Partnership
Stronger health systems. Greater health impact. Increasing Access to Medicines through Accredited Drug Dispensing Outlets (ADDOs): An Innovative Public-Private Partnership American Chemical Society Webinar
More informationAnnex 2. GRADE glossary and summary of evidence tables
WHO/HTM/TB/2011.6b. GRADE glossary and summary of evidence tables GRADE glossary Absolute effect The absolute measure of intervention effects is the difference between the baseline risk of an outcome (for
More informationNutrition, Tuberculosis (and HIV) Andrew Thorne-Lyman, ScD MHS
Nutrition, Tuberculosis (and HIV) Andrew Thorne-Lyman, ScD MHS 1 Preview Overview of the epidemics How nutritional status influences TB transmission and treatment outcomes WHO Nutritional care and support
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Lancelot M. Pinto, MD, MSc Author Madhukar Pai, MD, PhD co-author and Series Editor Lancelot Pinto is a
More informationTB Vaccine Development Strategy Overview
TB Vaccine Development Strategy Overview October 28, 2014 Angeline Nanni, MBA, MS Aeras Director, Global Access TB is Mother Nature s number one killer over the past centuries TB is spread through the
More informationPPFP Global Meeting Follow-up Workshop. Country Posters
PPFP Global Meeting Follow-up Workshop Country Posters Afghanistan Trained 12 family planning trainers in PPFP/PPIUD and developed plans to train 115 health care providers from 23 provinces in 4 regions
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More informationA Practical Approach to the Prevention and Control of Johnes Disease. R. J. Sibley BVSc HonFRCVS Myhealthyherd.com United Kingdom
A Practical Approach to the Prevention and Control of Johnes Disease R. J. Sibley BVSc HonFRCVS Myhealthyherd.com United Kingdom dicksibley@aol.com Key messages Key elements of Johnes Management Principles
More informationSIAPS Cameroon Key Achievements
SIAPS Cameroon Key Achievements 2012-2016 August 2016 Background USAID and the US Centers for Disease Control (CDC) are implementing the US President s Emergency Plan for AIDS Relief (PEPFAR) program
More informationUGANDA NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME
MINISTRY OF HEALTH UGANDA TIOL TUBERCULOSIS AND LEPROSY CONTROL PROGRAMME Revised Strategic Plan 2015/16-2019/20 Monitoring and Evaluation Plan Narrative of the Operational, Budget and Technical Assistance
More information4-6 Km-Mfx-Pto-Cfz-Z-H high-dose -E / 5 Mfx-Cfz-Z-E
Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions Version: 20 December 2016 These FAQs are to be read
More informationASEAN Declaration of Commitment on HIV and AIDS: Fast-Tracking and Sustaining HIV and AIDS Responses To End the AIDS Epidemic by 2030
ASEAN Declaration of Commitment on HIV and AIDS: Fast-Tracking and Sustaining HIV and AIDS Responses To End the AIDS Epidemic by 2030 1. WE, the Heads of State and Government of the Association of Southeast
More informationTrends in Testing for Mycobacterium tuberculosis Complex from US Public Health Laboratories,
Trends in Testing for Mycobacterium tuberculosis Complex from US Public Health Laboratories, 2009 2013 Frances Tyrrell, MT (ASCP), MPH Laboratory Consultant Laboratory Capacity Team (LCT)/DTBE ftyrrell@cdc.gov
More informationOverview of the Presentation
Overview of the Presentation Definitions(TBCase, MDR-TB & XDR-TB) Global Tuberculosis (TB,HIV/TB,MDR & XDR)Scenario & Trend Risk factor for TB Natural history of TB Types of TB & Trends of Extra Pulmonary
More informationThe Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific
Health System Strengthening and Sustaining the Response The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific Jintana Ngamvithayapong-Yanai, Ph.D. On behalf of TB/HIV Working Group, the
More informationTB/HIV Project in the Philippines. Yumiko Yanase
TB/HIV Project in the Philippines Yumiko Yanase 1 TB situation in the Philippines Global rank: 9th Incidence (all): 296 Prevalence (all): 458 TB mortality (all): 49 New MDR-TB: 3.2% Case types notified
More informationEstimating TB burden. Philippe Glaziou World Health Organization Accra, Ghana
Estimating TB burden Philippe Glaziou World Health Organization Accra, Ghana Outline Basic facts about TB epidemiology What should we expect with regards TB burden over time? Main indicators of TB disease
More informationEnd TB Strategy top 10 indicators: current status in participant countries
End TB Strategy top 10 indicators: current status in participant countries Dennis FALZON Global TB Programme, WHO/HQ Geneva Regional WHO / Global Fund meeting Kenya 20 September 2016 Objectives of the
More information